摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-[(dimethylamino)methyl]-7-hydroxy-1-(2-methoxyethyl)-N,N,2-trimethyl-1H-benzimidazole-5-carboxamide | 1015174-83-0

中文名称
——
中文别名
——
英文名称
6-[(dimethylamino)methyl]-7-hydroxy-1-(2-methoxyethyl)-N,N,2-trimethyl-1H-benzimidazole-5-carboxamide
英文别名
6-[(dimethylamino)methyl]-7-hydroxy-1-(2-methoxyethyl)-N,N,2-trimethylbenzimidazole-5-carboxamide
6-[(dimethylamino)methyl]-7-hydroxy-1-(2-methoxyethyl)-N,N,2-trimethyl-1H-benzimidazole-5-carboxamide化学式
CAS
1015174-83-0
化学式
C17H26N4O3
mdl
——
分子量
334.418
InChiKey
KBRMTSSJWBEKPZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    24
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    70.8
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Benzimidazole Derivatives as Selective Acid Pump Inhibitors
    申请人:Koike Hiroki
    公开号:US20100048532A1
    公开(公告)日:2010-02-25
    This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: R 1 , R 2 , R 3 , R 4 , A and E are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the method of treatment and the use, comprising such compounds for the treatment of a condition mediated by acid pump antagonistic activity such as, but not limited to, as gastrointestinal disease, gastroesophageal disease, gastroesophageal reflux disease (GERD), laryngopharyngeal reflux disease, peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcers, gastritis, infection of Helicobacter pylori , dyspepsia, functional dyspepsia, Zolliπger-Ellison syndrome, non-erosive reflux disease (NERD), visceral pain, cancer, heartburn, nausea, esophagitis, dysphagia, hypersalivation, airway disorders or asthma.
    本发明涉及式(I)的化合物或其药学上可接受的盐,其中:R1、R2、R3、R4、A和E分别如本文所述或其药学上可接受的盐,并含有此类化合物的组合物以及治疗和使用的方法,包括使用此类化合物治疗由酸泵拮抗活性介导的疾病,例如但不限于胃肠疾病、胃食管疾病、胃食管反流病(GERD)、喉咙咽部反流病、消化性溃疡、胃溃疡、十二指肠溃疡、NSAID引起的溃疡、胃炎、幽门螺杆菌感染、消化不良、功能性消化不良、Zolliπger-Ellison综合症、非侵蚀性反流病(NERD)、内脏疼痛、癌症、烧心、恶心、食管炎、吞咽困难、过多唾液、气道疾病或哮喘等病症。
  • Benzimidazole derivatives as selective acid pump inhibitors
    申请人:Koike Hiroki
    公开号:US08466166B2
    公开(公告)日:2013-06-18
    This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: R1, R2, R3, R4, A and E are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the method of treatment and the use, comprising such compounds for the treatment of a condition mediated by acid pump antagonistic activity such as, but not limited to, as gastrointestinal disease, gastroesophageal disease, gastroesophageal reflux disease (GERD), laryngopharyngeal reflux disease, peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcers, gastritis, infection of Helicobacter pylori, dyspepsia, functional dyspepsia, Zolliπger-Ellison syndrome, non-erosive reflux disease (NERD), visceral pain, cancer, heartburn, nausea, esophagitis, dysphagia, hypersalivation, airway disorders or asthma.
    本发明涉及式(I)的化合物或其药学上可接受的盐,其中:R1、R2、R3、R4、A和E均如本文所述或其药学上可接受的盐,以及含有这些化合物的组合物、治疗方法和使用,包括用于治疗酸泵拮抗活性介导的疾病,例如但不限于胃肠疾病、胃食管疾病、胃食管反流病(GERD)、喉咙咽反流病、消化性溃疡、胃溃疡、十二指肠溃疡、NSAID引起的溃疡、胃炎、幽门螺杆菌感染、消化不良、功能性消化不良、佐利-埃利森综合征、非侵蚀性反流病(NERD)、脏器疼痛、癌症、烧心、恶心、食管炎、吞咽困难、多口水、气道疾病或哮喘。
  • BENZIMIDAZOLE DERIVATIVES AS SELECTIVE ACID PUMP INHIBITORS
    申请人:RaQualia Pharma Inc
    公开号:EP2081939B1
    公开(公告)日:2011-06-15
  • US8466166B2
    申请人:——
    公开号:US8466166B2
    公开(公告)日:2013-06-18
  • WO2008/35195
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多